Checkpoint Inhibitor Refractory Cancer Drugs Market to Reach USD 95,548.35 Million by 2032 Amid Rising Post-Checkpoint Inhibitor Sequencing Demand and Combination Treatment ...

The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...

Credence Research Inc.: Checkpoint Inhibitor Refractory Cancer Drugs Market to Reach USD 95,548.35 Million by 2032 Amid Rising Post-Checkpoint Inhibitor Sequencing Demand and ...

The "Checkpoint Inhibitor Refractory Cancer Drugs Market - Growth, Share, Opportunities & Competitive Analysis, 2025 - 2032" report has been added to the ...

This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally

This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.

Eli Lilly: The Weight-Loss Craze Isn't Over

Orforglipron's launch and Medicare/Medicaid eligibility will expand Eli Lilly's addressable market and offset price erosion.

Nektar Therapeutics (NASDAQ:NKTR) Q4 2025 earnings call transcript

Nektar Therapeutics (NASDAQ:NKTR) Q4 2025 Earnings Call Transcript March 12, 2026 Nektar Therapeutics beats earnings expectations. Reported EPS is $-1.77756, expectations were $-2.47411. Operator: ...
Seeking Alpha

Incyte Corporation (INCY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Good morning, everyone. My name is Etzer Darout, Senior Biotech Analyst at Barclays. My pleasure to have Incyte joining us today, day 2 of our conference. With me, I have Bill Meury, President and ...

Endometriosis Market Expected to Achieve Significant CAGR During the Forecast Period (2026-2036) Driven by Innovative Treatment Options | DelveInsight

The endometriosis market is expected to grow steadily over the forecast period (2026--2036), driven by rising disease awareness, improving diagnosis rates, and advancements in noninvasive diagnostic ...

Pharvaris N.V.: Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology

Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights into clinically meaningful changes in HAE attack symptoms, and support for hierarchical ranking of RAP ...

Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR ...

Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that nine oral and poster ...
Las Vegas Sun

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry ...
Labiotech.eu

Can Bristol Myers Squibb’s pipeline strategy offset a major patent cliff?

We examine Bristol Myers Squibb’s pipeline strategy and therapeutic priorities in 2026, as it faces a major patent cliff in the coming years.

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung ...